| __timestamp | Halozyme Therapeutics, Inc. | Novartis AG |
|---|---|---|
| Wednesday, January 1, 2014 | 22732000 | 17345000000 |
| Thursday, January 1, 2015 | 29245000 | 17404000000 |
| Friday, January 1, 2016 | 33206000 | 17520000000 |
| Sunday, January 1, 2017 | 31152000 | 17175000000 |
| Monday, January 1, 2018 | 10136000 | 18407000000 |
| Tuesday, January 1, 2019 | 45546000 | 14425000000 |
| Wednesday, January 1, 2020 | 43367000 | 15121000000 |
| Friday, January 1, 2021 | 81413000 | 15867000000 |
| Saturday, January 1, 2022 | 139304000 | 15486000000 |
| Sunday, January 1, 2023 | 192361000 | 12472000000 |
| Monday, January 1, 2024 | 159417000 | 12827000000 |
Cracking the code
In the ever-evolving pharmaceutical landscape, understanding cost structures is crucial. This analysis delves into the cost of revenue for Novartis AG and Halozyme Therapeutics, Inc. from 2014 to 2023. Over this period, Novartis AG consistently maintained a high cost of revenue, peaking in 2018 with a 15% increase from 2014. However, a notable decline of 28% was observed by 2023, reflecting strategic shifts or market dynamics. In contrast, Halozyme Therapeutics, Inc. exhibited a remarkable growth trajectory, with its cost of revenue surging by over 740% from 2014 to 2023. This stark contrast highlights the differing operational scales and market strategies of these two companies. As Novartis navigates its mature market position, Halozyme's rapid expansion underscores its aggressive growth strategy in the biotech sector.
Cost of Revenue: Key Insights for Johnson & Johnson and Halozyme Therapeutics, Inc.
Cost of Revenue: Key Insights for Novartis AG and Gilead Sciences, Inc.
Analyzing Cost of Revenue: Novartis AG and Sarepta Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Novartis AG and Halozyme Therapeutics, Inc.
Analyzing Cost of Revenue: Novartis AG and Bausch Health Companies Inc.
Analyzing Cost of Revenue: Novartis AG and Iovance Biotherapeutics, Inc.
Cost of Revenue Trends: Novartis AG vs Travere Therapeutics, Inc.
Cost of Revenue Trends: Novartis AG vs BioCryst Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Novartis AG vs MiMedx Group, Inc.
Cost of Revenue: Key Insights for United Therapeutics Corporation and Halozyme Therapeutics, Inc.
Cost of Revenue Trends: Halozyme Therapeutics, Inc. vs Iovance Biotherapeutics, Inc.
Cost Insights: Breaking Down Halozyme Therapeutics, Inc. and Evotec SE's Expenses